Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ishwaria M Subbiah

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
Oncotarget|February 9, 2013
Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trialsIshwaria M Subbiah, Vivek Subbiah, Apostolia M Tsimberidou, et al.
Cancers|September 19, 2020
Trial Sponsorship and Time to Reporting for Phase 3 Randomized Cancer Clinical TrialsTimothy A Lin, Clifton David Fuller, Vivek Verma, et al.
JCO Oncology Practice|March 21, 2022
Social Media and Professional Development for Oncology ProfessionalsAnusha Chidharla, Audun Utengen, Deanna J Attai, et al.
JNCI Cancer Spectrum|April 27, 2023
Feasibility and acceptability of an online intervention to enhance hopefulness among oncology professionalsBenjamin W Corn, David B Feldman, Ishwaria M Subbiah, et al.
Journal of Patient-Reported Outcomes|May 26, 2023
Measuring symptom burden in patients with cancer during a pandemic: the MD Anderson symptom inventory for COVID-19 (MDASI-COVID)Loretta A Williams, Meagan S Whisenant, Tito R Mendoza, et al.
JCO Oncology Practice|October 6, 2025
ASCO State of Cancer Care in America Special Report 2025: Access to Cancer Clinical Trials in the United StatesErin P Balogh, Laura A Levit, Joseph M Unger, et al.
Elife|February 7, 2023
Long COVID in cancer patients: preponderance of symptoms in majority of patients over long time periodHiba Dagher, Anne-Marie Chaftari, Ishwaria M Subbiah, et al.
Journal of Hematology & Oncology|June 12, 2015
STUMP un"stumped": anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusionVivek Subbiah, Caitlin McMahon, Shreyaskumar Patel, et al.
European Journal of Cancer (Oxford, England : 1990)|July 24, 2020
Progression-free survival is a suboptimal predictor for overall survival among metastatic solid tumour clinical trialsDario Pasalic, Gwendolyn J McGinnis, C David Fuller, et al.
Journal of Geriatric Oncology|November 13, 2019
Decreasing incidence of upper age restriction enrollment criteria among cancer clinical trialsEthan B Ludmir, Ishwaria M Subbiah, Walker Mainwaring, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
Oncotarget|February 9, 2013
Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trialsIshwaria M Subbiah, Vivek Subbiah, Apostolia M Tsimberidou, et al.
Cancers|September 19, 2020
Trial Sponsorship and Time to Reporting for Phase 3 Randomized Cancer Clinical TrialsTimothy A Lin, Clifton David Fuller, Vivek Verma, et al.
JCO Oncology Practice|March 21, 2022
Social Media and Professional Development for Oncology ProfessionalsAnusha Chidharla, Audun Utengen, Deanna J Attai, et al.
JNCI Cancer Spectrum|April 27, 2023
Feasibility and acceptability of an online intervention to enhance hopefulness among oncology professionalsBenjamin W Corn, David B Feldman, Ishwaria M Subbiah, et al.
Journal of Patient-Reported Outcomes|May 26, 2023
Measuring symptom burden in patients with cancer during a pandemic: the MD Anderson symptom inventory for COVID-19 (MDASI-COVID)Loretta A Williams, Meagan S Whisenant, Tito R Mendoza, et al.
JCO Oncology Practice|October 6, 2025
ASCO State of Cancer Care in America Special Report 2025: Access to Cancer Clinical Trials in the United StatesErin P Balogh, Laura A Levit, Joseph M Unger, et al.
Elife|February 7, 2023
Long COVID in cancer patients: preponderance of symptoms in majority of patients over long time periodHiba Dagher, Anne-Marie Chaftari, Ishwaria M Subbiah, et al.
Journal of Hematology & Oncology|June 12, 2015
STUMP un"stumped": anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusionVivek Subbiah, Caitlin McMahon, Shreyaskumar Patel, et al.
European Journal of Cancer (Oxford, England : 1990)|July 24, 2020
Progression-free survival is a suboptimal predictor for overall survival among metastatic solid tumour clinical trialsDario Pasalic, Gwendolyn J McGinnis, C David Fuller, et al.
Journal of Geriatric Oncology|November 13, 2019
Decreasing incidence of upper age restriction enrollment criteria among cancer clinical trialsEthan B Ludmir, Ishwaria M Subbiah, Walker Mainwaring, et al.
Pageof 6